Akorn recruits Boothe as new chief executive

 Akorn recruits Boothe as new chief executive
Douglas Boothe has worked for Actavis, Impax and Perrigo

24 December 2018 - Deborah Wilkes

Akorn has appointed Douglas Boothe as president and chief executive officer with effect from 1 January 2019.

The US-based generics, consumer healthcare and animal health company said Boothe was an "industry veteran with extensive accomplishments in the specialty, generic and OTC pharmaceuticals business".

Most recently, Boothe was president of the USD600 million Generics Division of Impax Laboratories. He has also worked for Actavis and Perrigo.

Commenting on the appointment, Akorn's chairman Alan Weinstein said: "After a comprehensive search, Doug quickly rose to the top of the list due to his proven track record in helping build businesses, navigate regulatory complexities and guide companies through competitive market environments."

Boothe replaces Raj Rai who recently decided to retire from Akorn (click here to read the News story).

News of Rai's retirement came soon after the Delaware Chancery Court in the US ruled that Germany's Fresenius could terminate its planned USD4.75 billion acquisition of Akorn. The Supreme Court of the State of Delaware rejected Akorn's appeal against the judgement.

Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions

Back to Industry News

Share this page: